SYDNEY, AUSTRALIA – June 25, 2019 – Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune diseases, announces that it has completed patient enrolment of the Phase IIb Active
226 patients with metastatic breast cancer have been enrolled in the AIPAC study
Combination of eftilagimod alpha, an antigen presenting cell (APC) activator, administered in combination with chemotherapy is designed to boost the T-Cell immune responses against tumours
Read-out of progression-free survival (PFS) primary endpoint expected to occur in Q1 of calendar year 2020
Immunotherapy PAClitaxel (AIPAC) clinical trial in HER2-negative/ Hormone Receptor positive (HR+) metastatic breast cancer (MBC).
For further information please download the attached PDF:
Download this document